During the morning session, Houw Television announced an upward revision to its full-year operating profit forecast, while Relo Group announced that it would make Singapore-based ATIV Medical a subsidiary. Supertool reported lower first-half profit and set a share buyback limit. Imamura Securities reported higher first-half profit, and Kiraboshi FG announced an increase in its holdings of shares. Ribomic revised its full-year earnings forecast upward.
Houw Television raised its consolidated operating profit forecast for the fiscal year ending January 2027 from the previous ¥50 million to a range of ¥100 million to ¥200 million. Following strong performance in the first half from June to July, the company disclosed a range after taking into account shifts in the timing of second-half sales and the impact of cost reductions.
Relo Group decided to acquire shares in Singapore-based ATIV Medical and make it a subsidiary. The acquisition price is ¥1.68 billion, with synergies expected in its overseas assignment support business through the provision of medical services from before departure through life in the host country.
Supertool reported consolidated operating profit of ¥130 million for the first half of the fiscal year ending March 2027, down 34.4% year on year. The figure was below the previous forecast of ¥170 million, affected by higher raw material and energy costs. At the same time, it set a share buyback limit of 30,000 shares and ¥60 million, with the acquisition period running from 2026-10-21 to 2027-04-20.
Imamura Securities reported preliminary operating profit of ¥1.04 billion for the first half of the fiscal year ending March 2027, 2.1 times the year-earlier figure. The increase was supported by higher fees for the acceptance of share certificates and beneficiary certificates.
Ribomic rebounded for the first time in 14 days and raised its operating loss forecast for the fiscal year ending March 2027 from the previous loss of ¥1.55 billion to a loss of ¥1.48 billion. The revision reflects expected revenue recognition from an evaluation agreement for its DDS aptamer technology, as well as lower-than-expected research and development expenses.